This site is intended for healthcare professionals outside the US


Print |

Despite current treatment options, a substantial proportion of patients do not achieve biochemical control.

During transsphenoidal surgery2-5

  • 50% of tumors are not fully resected

After transsphenoidal surgery6

  • 30%45% of patients do not achieve a successful surgical cure and require medical therapy

After medical treatment with first-generation somatostatin analogs (SSAs)7

Medical Treatment With First-Generation SSAs

Effective management includes a comprehensive strategy to help optimize patient outcomes8-10:

  • Monitoring biochemical control
  • Managing comorbidities
  • Improving signs and symptoms
  • Controlling the tumor mass while preserving function
Learn about the possible treatment options for acromegaly patients.

1. Bex M, Abs R, T'Sjoen G, et al. AcroBel—the Belgian registry on acromegaly: a survey of the 'real-life' outcome in 418 acromegalic subjects. Eur J Endocrinol. 2007;157(4):399-409. 2. Theodosopoulos PV, Leach J, Kerr RG, et al. Maximizing the extent of tumor resection during transsphenoidal surgery for pituitary macroadenomas: can endoscopy replace intraoperative magnetic resonance imaging? J Neurosurg. 2010;112(4):736-743. 3. Bohinski RJ, Warnick RE, Gaskill-Shipley MF, et al. Intraoperative magnetic resonance imaging to determine the extent of resection of pituitary macroadenomas during transsphenoidal microsurgery. Neurosurgery. 2001;49(5):1133-1144. 4. Fahlbusch R, von Keller B, Ganslandt O, Kreutzer J, Nimsky C. Transsphenoidal surgery in acromegaly investigated by intraoperative high-field magnetic resonance imaging. Eur J Endocrinol. 2005;153(2):239-248. 5. Nimsky C, von Keller B, Ganslandt O, Fahlbusch R. Intraoperative high-field magnetic resonance imaging in transsphenoidal surgery of hormonally inactive pituitary macroadenomas. Neurosurgery. 2006;59(1):105-114. 6. Ayuk J, Sheppard MC. Growth hormone and its disorders. Postgrad Med J. 2006;82(963):24-30. 7. Carmichael JD, Bonert VS, Nuño M, Ly D, Melmed S. Acromegaly clinical trial methodology impact on reported biochemical efficacy rates of somatostatin receptor ligand treatments: a meta-analysis. J Clin Endocrinol Metab. 2014;99(5):1825-1833. 8. Melmed S, Colao A, Barkan A, et al. Guidelines for acromegaly management: an update. J Clin Endocrinol Metab. 2009;94(5):1509-1517. 9. Giustina A, Chanson P, Bronstein MD, et al. A consensus on criteria for cure of acromegaly. J Clin Endocrinol Metab. 2010;95(7):3141-3148. 10. Katznelson L, Atkinson JLD, Cook DM, Ezzat SZ, Hamrahian AH, Miller KK. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly—2011 update. Endocr Pract. 2011;17(suppl 4):1-44.

Please see the Summary of Product Characteristics.